Skip to main content

Market Overview

Amicus Therapeutics Building Rare Disease Treatment Strategy; Bank Of America Initiates At Buy

Amicus Therapeutics Building Rare Disease Treatment Strategy; Bank Of America Initiates At Buy

Bank of America's Peter Stapor initiated a Buy rating on Amicus Therapeutics, Inc. (NASDAQ: FOLD) with a price target of $10.00.

The leading drug in the company's portfolio is migalastat (Galafold) for a rare disease (Fabry disease), which results in enzyme deficiency and can lead to organ failure. Migalastat is a convenient alternative to other treatments as it can be taken orally. It is pending approval from Europe's Committee for Medicinal Products for Human Use.

Related Link: Here's Why Wells Fargo Doesn't Like Valeant's Big Bonuses

The acquisition of Scioderm added SD-101 (Zorblisa) to the company's portfolio. Zorblisa is in its phase three trial. It is being developed to treat Epidermolysis Bullosa (EB) a rare disease that affects infants and results in fragile skin and blisters and open wounds. These symptoms increase risk for complications such as sepsis and even squamous cell carcinoma. There are no approved treatments, and Zorblisa would be able to corner this market quickly. Its "phase 2b data was encouraging" and "doctors indicate Zorblisa could have wide use," Stapor noted.

Amicus is developing a compound to treat a third rare genetic disease (Pompe). Phase I/II is expected this year. Amicus Therapeutics is building a strong platform in rare disease treatment and with few to no drugs to compete against the upsides of this strategy seem large.

Latest Ratings for FOLD

Apr 2021Cantor FitzgeraldUpgradesNeutralOverweight
Mar 2021SVB LeerinkMaintainsMarket Perform
Mar 2021StifelInitiates Coverage OnHold

View More Analyst Ratings for FOLD
View the Latest Analyst Ratings


Related Articles (FOLD)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas Health Care Price Target Initiation Analyst Ratings Trading Ideas

Latest Ratings

RAREMorgan StanleyMaintains170.0
PNCMorgan StanleyMaintains192.0
PGMorgan StanleyMaintains155.0
OXYMorgan StanleyMaintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at